His main research concerns Cancer research, Immunology, Lung cancer, Immune system and Internal medicine. His Cancer research research includes themes of Cell growth, Mutation, Gene, Gefitinib and TGF beta 1. In Immunology, David P. Carbone works on issues like Cancer, which are connected to Cell culture.
David P. Carbone has included themes like Carcinogenesis, Carcinoma, Docetaxel and Adenocarcinoma in his Lung cancer study. His Immune system research is multidisciplinary, incorporating elements of Vascular endothelial growth factor A, Cytotoxic T cell and Stem cell. The various areas that he examines in his Internal medicine study include Endocrinology, Gene rearrangement and Oncology.
His primary areas of study are Lung cancer, Cancer research, Internal medicine, Oncology and Cancer. His Lung cancer research incorporates elements of Carcinoma, Disease and Epidermal growth factor receptor. As part of the same scientific family, David P. Carbone usually focuses on Cancer research, concentrating on Immunology and intersecting with Cytotoxic T cell.
His Internal medicine study frequently links to other fields, such as Endocrinology. His Oncology research includes elements of Surgery, Nivolumab, Clinical trial and Lung. His Immune system study combines topics from a wide range of disciplines, such as Vascular endothelial growth factor and Notch signaling pathway.
David P. Carbone mainly investigates Internal medicine, Oncology, Cancer research, Lung cancer and Immunotherapy. His work carried out in the field of Oncology brings together such families of science as Pembrolizumab, Atezolizumab, Cancer and First line. His Cancer study incorporates themes from Microbiome and Melanoma.
His Cancer research research incorporates themes from Exome sequencing, CD8, Immune system and Tyrosine-kinase inhibitor. His work in Lung cancer addresses subjects such as Point mutation, which are connected to disciplines such as Somatic cell and KRAS. His work on Immune checkpoint inhibitors as part of general Immunotherapy study is frequently linked to Center, therefore connecting diverse disciplines of science.
David P. Carbone mostly deals with Internal medicine, Lung cancer, Oncology, Cancer research and Immunotherapy. His research integrates issues of Mutation, Gene, Regimen and Clinical trial in his study of Lung cancer. His Oncology research is multidisciplinary, incorporating perspectives in Biomarker, Randomized controlled trial, Atezolizumab and Lung.
His study in Cancer research is interdisciplinary in nature, drawing from both Cell, T cell immunity, Immune system, Kinase and Programmed cell death. His Immune system study integrates concerns from other disciplines, such as Cytotoxic T cell, Antibody and microRNA, Circulating MicroRNA. David P. Carbone has researched Immunotherapy in several fields, including Microbiome, Concomitant, Antibiotics and Hazard ratio.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Comprehensive genomic characterization of squamous cell lung cancers
Peter S. Hammerman;Doug Voet;Michael S. Lawrence;Douglas Voet.
Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells.
Dmitry I. Gabrilovich;Dmitry I. Gabrilovich;Hailei L. Chen;Khaled R. Girgis;H. Thomas Cunningham.
Nature Medicine (1996)
First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
David P. Carbone;Martin Reck;Luis Paz-Ares;Benjamin Creelan.
The New England Journal of Medicine (2017)
ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
Kristin Bergethon;Alice T. Shaw;Sai Hong Ignatius Ou;Ryohei Katayama.
Journal of Clinical Oncology (2012)
Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer.
Bond Almand;Joseph I. Clark;Ekaterina Nikitina;James van Beynen.
Journal of Immunology (2001)
Vascular Endothelial Growth Factor Inhibits the Development of Dendritic Cells and Dramatically Affects the Differentiation of Multiple Hematopoietic Lineages In Vivo
Dmitry Gabrilovich;Tadao Ishida;Tsunehiro Oyama;Sophia Ran.
Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis
Li Yang;Laura M. DeBusk;Koari Fukuda;Barbara Fingleton.
Cancer Cell (2004)
Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
Scott N. Gettinger;Leora Horn;Leena Gandhi;David R. Spigel.
Journal of Clinical Oncology (2015)
Abrogation of TGFβ signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis
Li Yang;Jianhua Huang;Xiubao Ren;Agnieszka E. Gorska.
Cancer Cell (2008)
Clinical Significance of Defective Dendritic Cell Differentiation in Cancer
Bond Almand;John R. Resser;Brian Lindman;Sorena Nadaf.
Clinical Cancer Research (2000)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: